US › Healthcare

MBX Biosciences, Inc. Common Stock (MBX)

US · Healthcare · Biotechnology

$70.70+9.77%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-23.5M
Profit YoY
+1.5%
EPS
$-0.51
EPS estimate
$-0.58

EPS came in at -0.51 against a street estimate of -0.58 — a beat of 12.1%.

Key statistics

Market cap
$3.14B
Forward P/E
0.0
P/B
7.17
Book value
$9.20
EPS (TTM)
$-2.17
52-week high
$69.40
52-week low
$9.63
50-day MA
$47.88
200-day MA
$34.95

Analyst view

Analysts rate MBX Biosciences, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $77.00.

Shareholding

Insiders
2.70%
Institutions
120.43%

Largest institutional holders

FundStake
Frazier Life Sciences Management, L.P.13.98%
Orbimed Advisors, LLC7.64%
NEA Management Company, LLC7.59%
Wellington Management Company LLP6.71%
BlackRock Inc6.18%
FMR Inc6.17%
Deep Track Capital, LP5.79%
NVP Associates LLC4.49%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for MBX Biosciences, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.